// App-Quantinova.ai

156 : Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study.

Researchers

Presenter

  • Muthu Kumaran Veeraputhiran

Principal Investigators

  • Daniel H. Shevrin

  • Lance K. Heilbrun

  • Daryn Smith

  • Jing Li

  • Brenda Dickow

  • Elisabeth I. Heath

  • Ulka N. Vaishampayan

Medical Centers

  • NorthShore University HealthSystem, Evanston, IL

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Karmanos Cancer Institute, Detroit, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • Phosphorylated-AKT

  • Circulating tumor cells

  • Prostate specific antigen

  • Serine/threonine-protein kinase mTOR

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Carboplatin

  • Everolimus

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01051570

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved